Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Microcap Kitchen Canadian Stocks -- Ignore unavailable to you. Want to Upgrade?

To: ayeyou who wrote (40908)	3/1/2016 12:57:15 PM
From: jorjen	1 Recommendation Recommended By El Canadiense Respond to of 49402

CZO I agree as the story gets stronger and stronger and keep in mind this company has increasing revenues and earnings-------is currently building a new larger facility, has a pipeline of new products-------and is quietly working behind the scenes that could be transformational.......the press release today about McMaster University is a good example

To: ayeyou who wrote (40908)	4/6/2016 8:51:16 AM
From: kidl	Read Replies (1) \| Respond to of 49402

Ceapro renews licence, distribution deal with Symrise Ceapro Inc (C:CZO) Shares Issued 62,635,821 Last Close 4/5/2016 $0.53 Wednesday April 6 2016 - News Release Mr. Gilles Gagnon reports CEAPRO ANNOUNCES RENEWAL OF A LONG TERM LICENSE AND DISTRIBUTION AGREEMENT WITH SYMRISE Ceapro Inc. has signed a new long-term agreement with multinational Symrise AG, based in Germany, for the distribution and commercialization of Ceapro's high-value active ingredients to major key international players in the cosmetic market. The financial terms of the agreement were not disclosed. However, Symrise will provide Ceapro with financial support under the form of a significant line of credit until Jan. 1, 2019. "Symrise is a long-term partner of Ceapro, and we are very pleased to have renewed this agreement. Their continued partnership and financial support should enable us to accelerate the growth of our cosmeceuticals base business. We are delighted for the vote of confidence towards our company and especially for the recognition of the quality and uniqueness of Ceapro's products to be manufactured in our new and larger-capacity facility in Edmonton," said Gilles Gagnon, president and chief executive officer of Ceapro. "We are confident that our partnership with Symrise, one of the most respected players in our industry, will continue to equally aid in the achievement of our common goals," he added. "Ceapro and Symrise have a long-standing relationship in product development that has benefited both companies over the years," said Eder Ramos, president, cosmetic ingredients division, Symrise AG. "We see great value in this partnership and are very pleased to have secured the renewal of this agreement, which will continue to pave the way for future developments that should benefit both companies in creating value." © 2016 Canjex Publishing Ltd.